<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Neurosurgery Blog &#187; brain tumor</title>
	<atom:link href="http://www.neurosurgery-blog.com/archives/tag/brain-tumor/feed" rel="self" type="application/rss+xml" />
	<link>http://www.neurosurgery-blog.com</link>
	<description>Daily bibliographic and video review of the Neurosurgery Department. La Fe University Hospital. Valencia, Spain</description>
	<lastBuildDate>Thu, 09 Feb 2012 23:00:45 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.1</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Safety and Efficacy of Microporous Polysaccharide Hemospheres in Neurosurgery</title>
		<link>http://www.neurosurgery-blog.com/archives/3172</link>
		<comments>http://www.neurosurgery-blog.com/archives/3172#comments</comments>
		<pubDate>Mon, 19 Sep 2011 22:00:03 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Surgical technique]]></category>
		<category><![CDATA[brain tumor]]></category>
		<category><![CDATA[Microporous polysaccharide hemospheres]]></category>
		<category><![CDATA[Topical hemostatic agent]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=3172</guid>
		<description><![CDATA[Neurosurgery 69[ONS Suppl 1]:ons49–ons63, 2011 DOI: 10.1227/NEU.0b013e3182155a52
Effective hemostasis is mandatory for brain tumor surgery. Microporous polysaccharide hemosphere (MPH) powder, a white powder compounded from potato starch, was recently introduced for surgical and emergency application.
OBJECTIVE: To evaluate the safety and efficacy of MPHs in brain tumor surgery.
METHODS: Thirty-three patients (mean age, 58 years; range, 22-84 years) [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/09/Safety_and_Efficacy_of_Microporous_Polysaccharide.jpg"><img class="alignleft size-thumbnail wp-image-3173" title="Safety_and_Efficacy_of_Microporous_Polysaccharide" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/09/Safety_and_Efficacy_of_Microporous_Polysaccharide-150x150.jpg" alt="" width="150" height="150" /></a>Neurosurgery 69[ONS Suppl 1]:ons49–ons63, 2011 DOI: 10.1227/NEU.0b013e3182155a52</strong></p>
<p style="text-align: justify;">Effective hemostasis is mandatory for brain tumor surgery. Microporous polysaccharide hemosphere (MPH) powder, a white powder compounded from potato starch, was recently introduced for surgical and emergency application.</p>
<p style="text-align: justify;">OBJECTIVE: To evaluate the safety and efficacy of MPHs in brain tumor surgery.</p>
<p style="text-align: justify;">METHODS: Thirty-three patients (mean age, 58 years; range, 22-84 years) underwent microsurgical brain tumor resection. Final hemostasis was performed by topical application of MPHs, video recorded, and subsequently analyzed. Blood samples were taken before surgery, before application of hemospheres, and postoperatively. Volume measurements of the tumor, resection cavity, and postoperative hematoma were done on magnetic resonance imaging and computed tomography scans. Clinical examinations focused on neurological outcome, complications, and allergic reactions.</p>
<p style="text-align: justify;">RESULTS: Effective hemostasis was achieved by exclusive use of MPHs in 32 patients. In 1 patient, a single arterial bleeding underwent additional bipolar electrocauterization. Mean operative time was 156.8 minutes (range, 60-235 minutes). Hemostasis with MPHs required 57 seconds (mean; range, 8-202 seconds). Subjective neurosurgeons’ ranking of the hemostasis effect indicated excellent satisfaction. For the first 3 months, there was no hemospheres-related postoperative neurological worsening, no signs of allergic reaction, and no embolic complications. Early postoperative and 3-month follow-up magnetic resonance imaging and computed tomography scans excluded any expansive bleeding complication. As early as postoperative day 1, MPHs were no longer detected. There was no tumor mimicking contrast enhancement.</p>
<p style="text-align: justify;">CONCLUSION: In neurosurgery, MPHs allow fast and effective minimally invasive hemostasis. In this small case series, no adverse reactions were found.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/3172/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Preoperative Functional Mapping for Rolandic Brain Tumor Surgery: Comparison of Navigated Transcranial Magnetic Stimulation to Direct Cortical Stimulation</title>
		<link>http://www.neurosurgery-blog.com/archives/3133</link>
		<comments>http://www.neurosurgery-blog.com/archives/3133#comments</comments>
		<pubDate>Thu, 08 Sep 2011 22:00:12 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Neuronavigation]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Surgical technique]]></category>
		<category><![CDATA[brain tumor]]></category>
		<category><![CDATA[Direct cortical stimulation]]></category>
		<category><![CDATA[Motor cortex]]></category>
		<category><![CDATA[Preoperative mapping]]></category>
		<category><![CDATA[Transcranial magnetic stimulation]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=3133</guid>
		<description><![CDATA[Neurosurgery 69:581–589, 2011 DOI: 10.1227/NEU.0b013e3182181b89
Transcranial magnetic stimulation (TMS) is the only noninvasive method for presurgical stimulation mapping of cortical function. Recent technical advancements have significantly increased the focality and usability of the method.
OBJECTIVE: To compare the accuracy of a 3-dimensional magnetic resonance imaging– navigated TMS system (nTMS) with the gold standard of direct cortical stimulation [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/09/Preoperative_Functional_Mapping_for_Rolandic_Brain.jpg"><img class="alignleft size-thumbnail wp-image-3134" title="Preoperative_Functional_Mapping_for_Rolandic_Brain" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/09/Preoperative_Functional_Mapping_for_Rolandic_Brain-150x150.jpg" alt="" width="150" height="150" /></a>Neurosurgery 69:581–589, 2011 DOI: 10.1227/NEU.0b013e3182181b89</strong></p>
<p style="text-align: justify;">Transcranial magnetic stimulation (TMS) is the only noninvasive method for presurgical stimulation mapping of cortical function. Recent technical advancements have significantly increased the focality and usability of the method.</p>
<p style="text-align: justify;">OBJECTIVE: To compare the accuracy of a 3-dimensional magnetic resonance imaging– navigated TMS system (nTMS) with the gold standard of direct cortical stimulation (DCS).</p>
<p style="text-align: justify;">METHODS: The primary motor areas of 20 patients with rolandic tumors were mapped preoperatively with nTMS at 110% of the individual resting motor threshold. Intraoperative DCS was available from 17 patients. The stimulus locations eliciting the largest electromyographic response in the target muscles (‘‘hotspots’’) were determined for both methods.</p>
<p style="text-align: justify;">RESULTS: The nTMS and DCS hotspots were located on the same gyrus in all cases. The mean 6 SEM distance between the nTMS and DCS hotspots was 7.83 6 1.18 mm for the abductor pollicis brevis (APB) muscle (n = 15) and 7.07 6 0.88 mm for the tibialis anterior muscle (n = 8). When a low number of DCS stimulations was performed, the distance between the nTMS and DCS hotspots increased substantially (r = 20.86 for APB). After the exclusion of the cases with , 15 DCS APB responses, the mean 6 SEM distance between the hotspots was only 4.70 6 1.09 mm for APB (n = 8).</p>
<p style="text-align: justify;">CONCLUSION: Peritumoral mapping of the motor cortex by nTMS agreed well with the gold standard of DCS. Thus, nTMS is a reliable tool for preoperative mapping of motor function.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/3133/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Application of intraoperative indocyanine green videoangiography to brain tumor surgery</title>
		<link>http://www.neurosurgery-blog.com/archives/2914</link>
		<comments>http://www.neurosurgery-blog.com/archives/2914#comments</comments>
		<pubDate>Wed, 20 Jul 2011 22:00:08 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Surgical technique]]></category>
		<category><![CDATA[brain tumor]]></category>
		<category><![CDATA[Indocyanine green]]></category>
		<category><![CDATA[Surgical microscope]]></category>
		<category><![CDATA[Videoangiography]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=2914</guid>
		<description><![CDATA[
Acta Neurochir (2011) 153:1487–1495. DOI 10.1007/s00701-011-1046-x
Videoangiography using indocyanine green (ICG) has been used in the ophthalmologic field for a long time. It was introduced to the neurosurgical field several years ago but has been limited to vascular surgeries. We applied ICG videoangiography to brain tumor surgery and evaluated the usefulness.
Methods Twenty-three patients with a brain [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/07/Application-of-intraoperative-indocyanine-green-videoangiography-to-brain-tumor-surgery.jpg"><img class="alignleft size-thumbnail wp-image-2916" title="Application of intraoperative indocyanine green videoangiography to brain tumor surgery" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/07/Application-of-intraoperative-indocyanine-green-videoangiography-to-brain-tumor-surgery-150x150.jpg" alt="" width="150" height="150" /></a></strong></p>
<p><strong>Acta Neurochir (2011) 153:1487–1495. DOI 10.1007/s00701-011-1046-x</strong></p>
<p style="text-align: justify;">Videoangiography using indocyanine green (ICG) has been used in the ophthalmologic field for a long time. It was introduced to the neurosurgical field several years ago but has been limited to vascular surgeries. We applied ICG videoangiography to brain tumor surgery and evaluated the usefulness.</p>
<p style="text-align: justify;">Methods Twenty-three patients with a brain tumor who underwent microsurgical resection were analyzed. The pathological diagnosis was meningioma in 15 patients, metastasis in three, glioma in three, and hemangioblastoma in two. A microscope with a special filter and infrared excitation light to illuminate the operating field was used in this study. The intravascular fluorescence was imaged with a video camera attached to the microscope. ICG was injected intravenously with the dose of 5–25 mg, and overall, ICG was injected intraoperatively 32 times.</p>
<p style="text-align: justify;">Results ICG videoangiography allowed for an excellent evaluation of blood flow in the tumoral and peri-tumoral vessels both before and after the resection in all cases.</p>
<p style="text-align: justify;">Conclusions ICG videoangiography is a useful method for monitoring blood flow in the exposed vessels during microsurgery for a brain tumor. This noninvasive method is simple, safe, cost-effective, and easily repeatable. Before resection, it provides information on the tumoral and peritumoral circulation including sequential visualization of vessels or direction of the blood flow. After resection, it checks the patency of the peri-tumoral vessels and is especially useful for the vein. This ICG videoangiography can be an alternative tool to intraoperative angiography or Doppler ultrasonography in selective cases.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/2914/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Quantitative fluorescence in intracranial tumor: implications for ALA-induced PpIX as an intraoperative biomarker</title>
		<link>http://www.neurosurgery-blog.com/archives/2865</link>
		<comments>http://www.neurosurgery-blog.com/archives/2865#comments</comments>
		<pubDate>Thu, 07 Jul 2011 22:00:12 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Surgical technique]]></category>
		<category><![CDATA[ALA]]></category>
		<category><![CDATA[biophotonics]]></category>
		<category><![CDATA[brain tumor]]></category>
		<category><![CDATA[fluorescence-guided resection]]></category>
		<category><![CDATA[Glioma]]></category>
		<category><![CDATA[light-transport modeling]]></category>
		<category><![CDATA[optical spectroscopy]]></category>
		<category><![CDATA[PpIX]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=2865</guid>
		<description><![CDATA[J Neurosurg 115:11–17, 2011. DOI: 10.3171/2011.2.JNS101451
Accurate discrimination between tumor and normal tissue is crucial for optimal tumor resection. Qualitative fluorescence of protoporphyrin IX (PpIX), synthesized endogenously following d-aminolevulinic acid (ALA) administration, has been used for this purpose in high-grade glioma (HGG). The authors show that diagnostically significant but visually imperceptible concentrations of PpIX can be [...]]]></description>
			<content:encoded><![CDATA[<p><strong><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/07/5ALA1.jpg"><img class="alignleft size-thumbnail wp-image-2867" title="5ALA" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/07/5ALA1-150x150.jpg" alt="" width="150" height="150" /></a>J Neurosurg 115:11–17, 2011. DOI: 10.3171/2011.2.JNS101451</strong></p>
<p style="text-align: justify;">Accurate discrimination between tumor and normal tissue is crucial for optimal tumor resection. Qualitative fluorescence of protoporphyrin IX (PpIX), synthesized endogenously following d-aminolevulinic acid (ALA) administration, has been used for this purpose in high-grade glioma (HGG). The authors show that diagnostically significant but visually imperceptible concentrations of PpIX can be quantitatively measured in vivo and used to discriminate normal from neoplastic brain tissue across a range of tumor histologies.</p>
<p style="text-align: justify;">Methods. The authors studied 14 patients with diagnoses of low-grade glioma (LGG), HGG, meningioma, and metastasis under an institutional review board–approved protocol for fluorescence-guided resection. The primary aim of the study was to compare the diagnostic capabilities of a highly sensitive, spectrally resolved quantitative fluorescence approach to conventional fluorescence imaging for detection of neoplastic tissue in vivo.</p>
<p style="text-align: justify;">Results. A significant difference in the quantitative measurements of PpIX concentration occurred in all tumor groups compared with normal brain tissue. Receiver operating characteristic (ROC) curve analysis of PpIX concentration as a diagnostic variable for detection of neoplastic tissue yielded a classification efficiency of 87% (AUC = 0.95, specificity = 92%, sensitivity = 84%) compared with 66% (AUC = 0.73, specificity = 100%, sensitivity = 47%) for conventional fluorescence imaging (p &lt; 0.0001). More than 81% (57 of 70) of the quantitative fluorescence measurements that were below the threshold of the surgeon’s visual perception were classified correctly in an analysis of all tumors.</p>
<p style="text-align: justify;">Conclusions. These findings are clinically profound because they demonstrate that ALA-induced PpIX is a targeting biomarker for a variety of intracranial tumors beyond HGGs. This study is the first to measure quantitative ALA-induced PpIX concentrations in vivo, and the results have broad implications for guidance during resection of intracranial tumors.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/2865/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Intraoperative Confocal Microscopy for Brain Tumors: A Feasibility Analysis in Humans</title>
		<link>http://www.neurosurgery-blog.com/archives/2716</link>
		<comments>http://www.neurosurgery-blog.com/archives/2716#comments</comments>
		<pubDate>Thu, 02 Jun 2011 22:00:38 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Surgical technique]]></category>
		<category><![CDATA[brain tumor]]></category>
		<category><![CDATA[Confocal microscopy]]></category>
		<category><![CDATA[Glioma]]></category>
		<category><![CDATA[meningioma]]></category>
		<category><![CDATA[Neurolasermicroscopy]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=2716</guid>
		<description><![CDATA[Neurosurgery 68[ONS Suppl 2]:ons282–ons290, 2011. DOI: 10.1227/NEU.0b013e318212464e
The ability to diagnose brain tumors intraoperatively and identify tumor margins during resection could maximize resection and minimize morbidity. Advances in optical imaging enabled production of a handheld intraoperative confocal microscope.
OBJECTIVE: To present a feasibility analysis of the intraoperative confocal microscope for brain tumor resection.
METHODS: Thirty-three patients with brain [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2011/06/Confocalmicroscopy.jpg"><img class="alignleft size-thumbnail wp-image-2720" title="Confocalmicroscopy" src="http://www.neurosurgery-blog.com/wp-content/uploads/2011/06/Confocalmicroscopy-150x150.jpg" alt="" width="150" height="150" /></a><strong>Neurosurgery 68[ONS Suppl 2]:ons282–ons290, 2011. DOI: 10.1227/NEU.0b013e318212464e</strong></p>
<p style="text-align: justify;">The ability to diagnose brain tumors intraoperatively and identify tumor margins during resection could maximize resection and minimize morbidity. Advances in optical imaging enabled production of a handheld intraoperative confocal microscope.</p>
<p style="text-align: justify;">OBJECTIVE: To present a feasibility analysis of the intraoperative confocal microscope for brain tumor resection.</p>
<p style="text-align: justify;">METHODS: Thirty-three patients with brain tumor treated at Barrow Neurological Institute were examined. All patients received an intravenous bolus of sodium fluorescein before confocal imaging with the Optiscan FIVE 1 system probe. Optical biopsies were obtained within each tumor and along the tumor-brain interfaces. Corresponding pathologic specimens were then excised and processed. These data was compared by a neuropathologist to identify the concordance for tumor histology, grade, and margins.</p>
<p style="text-align: justify;">RESULTS: Thirty-one of 33 lesions were tumors (93.9%) and 2 cases were identified as radiation necrosis (6.1%). Of the former, 25 (80.6%) were intra-axial and 6 (19.4%) were extra-axial. Intra-axial tumors were most commonly gliomas and metastases, while all extra-axial tumors were meningiomas. Among high-grade gliomas, vascular neoproliferation, as well as tumor margins, were identifiable using confocal imaging. Meningothelial and fibrous meningiomas were distinct on confocal microcopy—the latter featured spindle-shaped cells distinguishable from adjacent parenchyma. Other tumor histologies correlated well with standard neuropathology tissue preparations.</p>
<p style="text-align: justify;">CONCLUSION: Intraoperative confocal microscopy is a practicable technology for the resection of human brain tumors. Preliminary analysis demonstrates reliability for a variety of lesions in identifying tumor cells and the tumor-brain interface. Further refinement of this technology depends upon the approval of tumor-specific fluorescent contrast agents for human use.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/2716/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Image-guided frameless stereotactic biopsy without intraoperative neuropathological examination. Clinical article</title>
		<link>http://www.neurosurgery-blog.com/archives/1459</link>
		<comments>http://www.neurosurgery-blog.com/archives/1459#comments</comments>
		<pubDate>Mon, 30 Aug 2010 04:00:12 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Neuronavigation]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Stereotactic neurosurgery]]></category>
		<category><![CDATA[ambulatory day-case surgery]]></category>
		<category><![CDATA[brain tumor]]></category>
		<category><![CDATA[intraoperative neuropathological examination]]></category>
		<category><![CDATA[multiple specimens]]></category>
		<category><![CDATA[stereotactic biopsy]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=1459</guid>
		<description><![CDATA[
Journal of Neurosurgery, August 2010 Volume 113, Number 2
DOI: 10.3171/2009.12.JNS09573
Stereotactic biopsy is a safe and effective technique for the diagnosis of brain tumors. The use of intraoperative neuropathological examination has been routinely advocated to increase diagnostic yield, but the procedure lengthens surgical time, may produce false-negative and -positive results, and current biopsy techniques have a [...]]]></description>
			<content:encoded><![CDATA[<div>
<div><a href="http://www.neurosurgery-blog.com/wp-content/uploads/2010/08/Dibujo1.jpg"><img class="alignleft size-full wp-image-1463" title="Dibujo" src="http://www.neurosurgery-blog.com/wp-content/uploads/2010/08/Dibujo1.jpg" alt="" width="126" height="146" /></a>Journal of Neurosurgery, August 2010 Volume 113, Number 2</div>
<div>DOI: 10.3171/2009.12.JNS09573</div>
<div style="text-align: justify;">Stereotactic biopsy is a safe and effective technique for the diagnosis of brain tumors. The use of intraoperative neuropathological examination has been routinely advocated to increase diagnostic yield, but the procedure lengthens surgical time, may produce false-negative and -positive results, and current biopsy techniques have a very low nondiagnostic rate. Therefore, the authors questioned the need for intraoperative histological evaluation.</div>
<div style="text-align: justify;">Methods</div>
<div style="text-align: justify;">The authors prospectively studied all patients undergoing image-guided biopsy under the care of a single surgeon (P.L.G.) between July 2005 and October 2007. A Stryker neuronavigation system with a trajectory guide was used to plan a single trajectory, and, using a side-cutting biopsy cannula, multiple biopsy samples were taken from between 1 and 4 sites within the tumor. Tissue was inspected macroscopically by the surgeon and was only submitted for neuropathological assessment postoperatively.</div>
<div style="text-align: justify;">Results</div>
<div style="text-align: justify;">One hundred thirty-four biopsies were performed during the study. A positive diagnosis was established in 133 cases (99.3%). One biopsy was negative (0.7%) and postoperative imaging (performed because the tissue was macroscopically normal) demonstrated inaccurate targeting of the lesion. Significant complications were seen in 3 patients (2.2%) who all had preoperative WHO performance scores of III or IV. Two patients suffered delayed deterioration and died due to probable surgical complications—one with thalamic glioblastoma multiforme (GBM) and one with gliomatosis cerebri. One patient with GBM suffered an intracerebral hematoma that was managed conservatively. Postoperative seizures were seen in 4 patients (3%), and 2 patients (1.5%) experienced a transient neurological deficit. Histological diagnosis showed a GBM in 64 cases, Grade III glioma in 19, Grade I or II in 23, metastasis in 10, lymphoma in 13, and other disease in 4. There were 32 patients discharged to home on the same day as surgery. Compared with the authors&#8217; previous retrospective audit into 127 biopsies, this technique showed improved diagnostic yield (99.3 vs 94.5%, p = 0.032) with fewer complications (2.2 vs 4.7% [not statistically significant]).</div>
<div style="text-align: justify;">Conclusions</div>
<div style="text-align: justify;">This technique of image-guided biopsy has high diagnostic yield with acceptably low morbidity and may be performed as a day case. Intraoperative neuropathological examination would not have increased the diagnostic yield further in this study, and its routine use may not be necessary. In the authors&#8217; department £70,350 (UK)/$114,522 (US) would have been saved by not using intraoperative neuropathology in this series. Therefore, intraoperative neuropathology should no longer be routinely recommended.</div>
</div>
<p><!-- /abstract content --></p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/1459/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>In pursuit of prognostic factors in children with pilocytic astrocytomas</title>
		<link>http://www.neurosurgery-blog.com/archives/544</link>
		<comments>http://www.neurosurgery-blog.com/archives/544#comments</comments>
		<pubDate>Thu, 21 Jan 2010 05:00:28 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Pediatrics]]></category>
		<category><![CDATA[brain tumor]]></category>
		<category><![CDATA[Galectin-3]]></category>
		<category><![CDATA[pediatric neurosurgery]]></category>
		<category><![CDATA[Pilocytic astrocytoma]]></category>
		<category><![CDATA[prognostic factors]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=544</guid>
		<description><![CDATA[Childs Nerv Syst (2010) 26:19–28 DOI 10.1007/s00381-009-0990-8
 
This study described a 23-year experience in the treatment of children with pilocytic astrocytomas (piloA) with the aim of identifying putative clinical, histopathological, and/or immunohistochemical features that could be related to the outcome of these patients.
Methods Clinical data of 31 patients under 18 years of age with piloA [...]]]></description>
			<content:encoded><![CDATA[<p style="margin: 0.0px 0.0px 0.0px 0.0px; text-align: justify; font: 12.0px Helvetica;"><span style="letter-spacing: 0.0px;">Childs Nerv Syst (2010) 26:19–28 DOI 10.1007/s00381-009-0990-8</span></p>
<p style="margin: 0.0px 0.0px 0.0px 0.0px; text-align: justify; font: 12.0px Helvetica; min-height: 14.0px;"><span style="letter-spacing: 0.0px;"> </span></p>
<p style="margin: 0.0px 0.0px 0.0px 0.0px; text-align: justify; font: 12.0px Helvetica;"><span style="letter-spacing: 0.0px;">This study described a 23-year experience in the treatment of children with pilocytic astrocytomas (piloA) with the aim of identifying putative clinical, histopathological, and/or immunohistochemical features that could be related to the outcome of these patients.</span></p>
<p style="margin: 0.0px 0.0px 0.0px 0.0px; text-align: justify; font: 12.0px Helvetica;"><span style="letter-spacing: 0.0px;">Methods Clinical data of 31 patients under 18 years of age with piloA were obtained from 1984 to 2006. </span></p>
<p style="margin: 0.0px 0.0px 0.0px 0.0px; text-align: justify; font: 12.0px Helvetica;"><span style="letter-spacing: 0.0px;">Results The mean age at the time of surgery was 7.8± 4.2 years (1 to 17 years), and the mean follow-up was 5.7± 5.4 years (1 to 20 years). The most common site of tumor formation was the cerebellum (17), followed by brainstem (4), optic chiasmatic hypothalamic region (4), cerebral hemisphere (3), cervical spinal cord (2), and optic nerve (1). Gross total resection (GTR) was achieved in 23 (74.1%), mainly in those with tumors located in the cerebellum and cerebral hemispheres (P=0.02). The global mortality rate was 6.4%. Nine patients were reoperated. Rosenthal fibers, eosinophilic granular bodies, microvascular proliferation, and lymphocytic infiltration were observed in most cases. The mean Ki-67LI was 4.4 ± 4.5%. In all cases, Gal-3 expression in tumor cells was observed with variable staining pattern. </span></p>
<p style="margin: 0.0px 0.0px 0.0px 0.0px; text-align: justify; font: 12.0px Helvetica;"><span style="letter-spacing: 0.0px;">Conclusions Aside from GTR, no other clinical, histopathological, or immunohistochemical features were found to be related to the prognosis. We postulate that strict follow- up is recommended if piloA is associated with high mitotic activity/Ki67-LI, or if GTR cannot be achieved at surgery. Tumor recurrence or progression of the residual lesion should be strictly observed. In some aspects, childhood piloA remains an enigmatic tumor.</span></p>
<div style="text-align: justify;"><span style="font-family: Helvetica, 'Times New Roman', 'Bitstream Charter', Times, serif; font-size: small;"><span style="line-height: normal;"><br />
</span></span></div>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/544/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Diagnostic value of proton magnetic resonance spectroscopy in the noninvasive grading of solid gliomas: comparison of maximum and mean choline values</title>
		<link>http://www.neurosurgery-blog.com/archives/363</link>
		<comments>http://www.neurosurgery-blog.com/archives/363#comments</comments>
		<pubDate>Wed, 18 Nov 2009 05:55:14 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Oncology]]></category>
		<category><![CDATA[brain tumor]]></category>
		<category><![CDATA[Choline]]></category>
		<category><![CDATA[Magnetic resonance spectroscopy]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=363</guid>
		<description><![CDATA[Neurosurgery 65:908–913, 2009 DOI: 10.1227/01.NEU.0000356982.82378.BA
 
Magnetic resonance spectroscopy is widely used in addition to magnetic resonance imaging in the characterization of brain tumors. Compounds containing choline (Cho) have an important role in the evaluation of tumor malignancy. For this purpose, various ratios of Cho and other metabolites, such as creatine (Cr), have been assessed. The [...]]]></description>
			<content:encoded><![CDATA[<p style="margin: 0.0px 0.0px 0.0px 0.0px; text-align: justify; font: 12.0px Helvetica;"><span style="letter-spacing: 0.0px;">Neurosurgery 65:908–913, 2009 DOI: 10.1227/01.NEU.0000356982.82378.BA</span></p>
<p style="margin: 0.0px 0.0px 0.0px 0.0px; text-align: justify; font: 12.0px Helvetica; min-height: 14.0px;"><span style="letter-spacing: 0.0px;"> </span></p>
<p style="margin: 0.0px 0.0px 0.0px 0.0px; text-align: justify; font: 12.0px Helvetica;"><span style="letter-spacing: 0.0px;">Magnetic resonance spectroscopy is widely used in addition to magnetic resonance imaging in the characterization of brain tumors. Compounds containing choline (Cho) have an important role in the evaluation of tumor malignancy. For this purpose, various ratios of Cho and other metabolites, such as creatine (Cr), have been assessed. The aim of this study was to compare normalized mean and maximum levels of Cho as single parameters in the noninvasive grading of gliomas.</span></p>
<p style="margin: 0.0px 0.0px 0.0px 0.0px; text-align: justify; font: 12.0px Helvetica;"><span style="letter-spacing: 0.0px;">METHODS: Proton spectroscopic imaging data of 63 patients with suspected World Health Organization (WHO) grade II or III gliomas were acquired at 3 T. Cho concentrations of the tumor were analyzed by a frequency domain fit and normalized to the corresponding contralateral healthy brain tissue. Metabolite images were used to determine the maximum and mean Cho as well as Cr concentrations of the tumor. Furthermore, contrast enhancement of the tumor was analyzed on standard magnetic resonance imaging. All patients subsequently underwent tumor resection or stereotactic biopsy to confirm diagnosis of glioma. Statistical analysis using the Kruskal-Wallis test, Mann-Whitney U test, and receiver operating characteristic curve analysis was performed with BiAS software (Epsilon Verlag GmbH, Frankfurt, Germany).</span></p>
<p style="margin: 0.0px 0.0px 0.0px 0.0px; text-align: justify; font: 12.0px Helvetica;"><span style="letter-spacing: 0.0px;">RESULTS: Histopathological examinations revealed WHO grades II (n=27), III (n=26), and IV (n=10). There was a statistically significant difference in both normalized maximum and mean Cho between WHO grade II and non-necrotic WHO grade III/IV gliomas (mean, 1.45 </span><span style="font: 8.0px Helvetica; letter-spacing: 0.0px;"><sup>±</sup></span><span style="letter-spacing: 0.0px;">0.28 versus 2.16±0.36, P&lt;0.05; maximum, 1.64±0.32 versus 3.32±0.55, P&lt;0.0001). Receiver operating characteristic analyses rendered a 2.02 cutoff value for maximum Cho with a sensitivity and specificity of 86.1% and 77.8%, respectively. For mean Cho, we found a cutoff value of 1.52 (sensitivity, 77.8%; specificity, 63.0%). The diagnostic accuracy of maximum Cho was superior to that of mean Cho and also the ratio of Cho/Cr (82.5% versus 71.4% and 72.1%, respectively), but all 3 parameters were superior to contrast enhancement of the tumor (61.9%).</span></p>
<p style="margin: 0.0px 0.0px 0.0px 0.0px; text-align: justify; font: 12.0px Helvetica;"><span style="letter-spacing: 0.0px;">CONCLUSION: Both maximum and mean Cho differ between low- and high-grade gliomas. Compared with contrast enhancement, mean Cho, and Cho/Cr, maximum Cho of the tumor provides the highest accuracy in discriminating between low- and high-grade tumors, indicating usefulness of this single parameter in the process of therapeutic decision making.</span></p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/363/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma</title>
		<link>http://www.neurosurgery-blog.com/archives/246</link>
		<comments>http://www.neurosurgery-blog.com/archives/246#comments</comments>
		<pubDate>Mon, 05 Oct 2009 04:00:53 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Oncology]]></category>
		<category><![CDATA[bevacizumab]]></category>
		<category><![CDATA[brain tumor]]></category>
		<category><![CDATA[Glioma]]></category>
		<category><![CDATA[Outcome]]></category>
		<category><![CDATA[recurrent glioblastoma]]></category>
		<category><![CDATA[survival]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=246</guid>
		<description><![CDATA[Journal of Clinical Oncology. DOI:10.1200/JCO.2008.19.8721
Purpose
We evaluated the efficacy of bevacizumab (Avastin TM), alone and in combination with irinotecan, in patients with recurrent glioblastoma in a phase II, multicenter, open-label, noncomparative trial.
Patients and Methods
One hundred sixty-seven patients were randomly assigned to receive bevacizumab 10 mg/kg alone or in combination with irinotecan 340 mg/m2 or 125 mg/m2 [...]]]></description>
			<content:encoded><![CDATA[<p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica;">Journal of Clinical Oncology. DOI:10.1200/JCO.2008.19.8721</p>
<p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica;"><span style="letter-spacing: 0.0px;"><strong>Purpose</strong></span></p>
<p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica;"><span style="letter-spacing: 0.0px;">We evaluated the efficacy of bevacizumab (Avastin </span><span style="font: 7.0px Helvetica; letter-spacing: 0.0px;">TM</span><span style="letter-spacing: 0.0px;">), alone and in combination with irinotecan, in patients with recurrent glioblastoma in a phase II, multicenter, open-label, noncomparative trial.</span></p>
<p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica;"><span style="letter-spacing: 0.0px;"><strong>Patients and Methods</strong></span></p>
<p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica;"><span style="letter-spacing: 0.0px;">One hundred sixty-seven patients were randomly assigned to receive bevacizumab 10 mg/kg alone or in combination with irinotecan 340 mg/m2 or 125 mg/m2 (with or without concomitant enzyme-inducing antiepileptic drugs, respectively) once every 2 weeks. Primary end points were 6-month progression-free survival and objective response rate, as determined by independent radiology review. Secondary end points included safety and overall survival.</span></p>
<p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica;"><span style="letter-spacing: 0.0px;"><strong>Results</strong></span></p>
<p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica;"><span style="letter-spacing: 0.0px;">In the bevacizumab-alone and the bevacizumab-plus-irinotecan groups, estimated 6-month progression-free survival rates were 42.6% and 50.3%, respectively; objective response rates were 28.2% and 37.8%, respectively; and median overall survival times were 9.2 months and 8.7 months, respectively. There was a trend for patients who were taking corticosteroids at baseline to take stable or decreasing doses over time. Of the patients treated with bevacizumab alone or bevacizumab plus irinotecan, 46.4% and 65.8%, respectively, experienced grade  3 adverse events, the most common of which were hypertension (8.3%) and convulsion (6.0%) in the bevacizumab-alone group and convulsion (13.9%), neutropenia (8.9%), and fatigue (8.9%) in the bevacizumab-plus-irinotecan group. Intracranial hemorrhage was noted in two patients (2.4%) in the bevacizumab-alone group (grade 1) and in three patients (3.8%) patients in the bevacizumabplus-irinotecan group (grades 1, 2, and 4, respectively).</span></p>
<p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica;"><span style="letter-spacing: 0.0px;"><strong>Conclusion</strong></span></p>
<p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica;"><span style="letter-spacing: 0.0px;">Bevacizumab, alone or in combination with irinotecan, was well tolerated and active in recurrent glioblastoma.</span></p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/246/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Neurosurgical management of intractable rolandic epilepsy in children: role of resection in eloquent cortex</title>
		<link>http://www.neurosurgery-blog.com/archives/238</link>
		<comments>http://www.neurosurgery-blog.com/archives/238#comments</comments>
		<pubDate>Thu, 01 Oct 2009 07:08:39 +0000</pubDate>
		<dc:creator>cba</dc:creator>
				<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Pediatrics]]></category>
		<category><![CDATA[brain tumor]]></category>
		<category><![CDATA[cortical resection]]></category>
		<category><![CDATA[intractable epilepsy]]></category>
		<category><![CDATA[magnetoencephalography]]></category>
		<category><![CDATA[Outcome]]></category>
		<category><![CDATA[rolandic region]]></category>

		<guid isPermaLink="false">http://www.neurosurgery-blog.com/?p=238</guid>
		<description><![CDATA[J Neurosurg Pediatrics 4:199-216, 2009. DOI: 10.3171/2009.3.PEDS08459
Object. The authors undertook this study to review their experience with cortical resections in the rolandic region in children with intractable  epilepsy.
Methods. The authors retrospectively reviewed the medical records obtained in 22 children with intractable epilepsy arising from the rolandic region. All patients underwent preoperative   electroencephalography (EEG), MRimaging, prolonged [...]]]></description>
			<content:encoded><![CDATA[<p>J Neurosurg Pediatrics 4:199-216, 2009. DOI: 10.3171/2009.3.PEDS08459</p>
<p><strong>Object</strong>. The authors undertook this study to review their experience with cortical resections in the rolandic region in children with intractable  epilepsy.<br />
<strong>Methods</strong>. The authors retrospectively reviewed the medical records obtained in 22 children with intractable epilepsy arising from the rolandic region. All patients underwent preoperative   electroencephalography (EEG), MRimaging, prolonged video-EEG recordings, functional MR imaging, magnetoencephalography, and in some instances PET/SPECT studies. In 21 patients invasive subdural grid and depth electrode monitoring was performed. Resection of the epileptogenic zones in the rolandic region was undertaken in all cases. Seizure outcome was graded according to the Engel classification. Functional outcome was determined using validated outcome scores.<br />
<strong>Results</strong>. There were 10 girls and 12 boys, whose mean age at seizure onset was 3.2 years. The mean age at surgery was 10 years. Seizure duration prior to surgery was a mean of 7.4 years. Nine patients had preoperative hemiparesis.<br />
Neuropsychological testing revealed impairment in some domains in 19 patients in whom evaluation was possible. Magnetic resonance imaging abnormalities were identified in 19 patients. Magnetoencephalography was performed in all patients and showed perirolandic spike clusters on the affected side in 20 patients. The mean duration of invasive monitoring was 4.2 days. The mean number of seizures during the period of invasive monitoring was 17. All patients underwent resection that involved primary motor and/or sensory cortex. The most common pathological entity encountered was cortical dysplasia, in 13 children. Immediately postoperatively, 20 patients had differing degrees of hemiparesis, from mild to severe. The hemiparesis improved in all affected patients by 3–6 months postoperatively. With a mean follow-up of 4.1 years (minimum 2 years), seizure outcome in 14 children (64%) was Engel Class I and seizure outcome in 4 (18%) was Engel Class II. In this series, seizure outcome following perirolandic resection was intimately related to the child’s age at the time of surgery. By univariate logistic regression analysis, age at surgery was a statistically significant factor predicting seizure outcome (p &lt; 0.024).<br />
<strong>Conclusions</strong>. Resection of rolandic cortex for intractable epilepsy is possible with expected morbidity. Accurate mapping of regions of functional cortex and epileptogenic zones may lead to improved seizure outcome in children with intractable rolandic epilepsy. It is important to counsel patients and families preoperatively to prepare them for possible worsened functional outcome involving motor, sensory and/or language pathways.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.neurosurgery-blog.com/archives/238/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

